抗血管生成靶向治疗联合化疗治疗晚期肺癌疗效及对癌胚抗原、肝肾功能、血压的影响

摘要/Abstract

摘要： 目的探讨抗血管生成靶向治疗联合化疗治疗晚期肺癌疗效及对癌胚抗原、肝肾功能、血压的影响。方法选取2020年11月~2021年11月于南通市肿瘤医院接受治疗的晚期肺癌患者共计78例,采用随机数表法将其分为对照组（n=39）和观察组（n=39）,对照组接受紫杉醇（白蛋白结合型）联合顺铂化疗,观察组在对照组治疗的基础上联合贝伐珠单抗治疗。比较两组临床治疗效果、血压情况、细胞角质蛋白19片段抗原21-1（CYFRA21-1）水平、糖类抗原125（CA125）水平、血清癌胚抗原（CEA）水平、血清丙氨酸氨基转移酶（ALT）水平、血清肌酐（Scr）水平、血清谷氨酰转肽酶（GGT）水平以及不良反应发生情况。结果比较两组患者临床治疗效果,观察组明显比对照组高（P<0.05）;比较两组患者治疗前收缩压、舒张压指标水平,差异无统计学意义（P>0.05）,两组患者治疗后收缩压、舒张压指标水平均有所上升,且观察组治疗后收缩压、舒张压指标水平高于对照组（P<0.05）;比较两组患者治疗前CYFRA21-1、CA125、CEA水平,差异无统计学意义（P>0.05）,比较两组患者治疗后CYFRA21-1、CA125、CEA水平,两组均有所下降,且观察组比对照组低（P<0.05）;比较两组治疗前ALT、Scr、GGT指标水平,差异无统计学意义（P>0.05）,比较两组治疗后ALT、Scr、GGT指标水平,两组均高于治疗前（P<0.05）,但两组治疗后ALT、Scr、GGT指标水平比较,差异无统计学意义（P>0.05）;比较两组患者血液学毒性骨髓抑制、胃肠道反应、皮肤反应等不良反应发生率,差异无统计学意义（P>0.05）。结论抗血管生成靶向治疗联合化疗治疗晚期肺癌患者,可提高临床效果,促使肿瘤标志物水平得以改善,且不会影响肝肾功能和增加不良反应,但是易提高患者血压水平,临床需继续深入研究。

关键词: 抗血管生成靶向治疗, 化疗, 晚期肺癌, 疗效, 癌胚抗原, 肝肾功能, 血压

Abstract: Objective To investigate the efficacy of anti-angiogenic targeted therapy combined with chemotherapy in the treatment of advanced lung cancer and its effect on carcinoembryonic antigen, liver and kidney function and blood pressure. Methods A total of 78 patients with advanced lung cancer who were treated in Nantong Cancer Hospital were selected as the research objects, and they were divided into control group (n=39) and observation group (n=39) by random number table method from November 2020 to November 2021. The control group received paclitaxel (albumin binding) combined with cisplatin chemotherapy, and the observation group was treated with bevacizumab on the basis of the treatment of the control group. The clinical treatment effect, blood pressure, cyto-keratin 19 fragment antigen 21-1 (CYFRA21-1) level, carbohydrate antigen 125 (CA125) level, serum cancer levels were compared between the two groups Carcinoembryonic antigen (CEA) level, serum alanine aminotransferase (ALT) level, serum creatinine (Scr) level, serum glutamyl transpeptidase (GGT) level and the occurrence of adverse reactions. Results The clinical treatment effect of the two groups of patients was compared, and the observation group was significantly higher than the control group (P<0.05); the systolic blood pressure and diastolic blood pressure index levels were compared between the two groups before treatment, and there was no statistical difference (P>0.05). After systolic blood pressure and diastolic blood pressure index levels, both groups increased, and the observation group was higher than the control group (P<0.05). compared the levels of CYFRA21-1, CA125, and CEA between the two groups after treatment, the two groups were decreased, and the observation group was lower than the control group (P<0.05). There was no statistical difference (P>0.05). Comparing the levels of ALT, Scr, and GGT between the two groups after treatment, the two groups were all higher than before treatment (P<0.05), but the levels of ALT, Scr, and GGT in the two groups after treatment There was no statistical difference between the two groups (P>0.05). There was no statistical difference in the incidence of adverse reactions such as hematological toxicity, myelosuppression, gastrointestinal reactions, and skin reactions between the two groups (P>0.05). Conclusion Anti-angiogenic targeted therapy combined with chemotherapy in the treatment of advanced lung cancer patients can improve the clinical effect, promote the improvement of tumor marker levels, and will not affect liver and kidney function and increase adverse reactions, but it is easy to increase the blood pressure level of patients, and clinical research needs to continue to deepen Research.

Key words: antiangiogenic targeted therapy, chemotherapy, advanced lung cancer, curative effect, carcinoembryonic antigen, liver and kidney function, blood pressure

中图分类号:

R734.2

王晓丽, 曹永峰, 周艳. 抗血管生成靶向治疗联合化疗治疗晚期肺癌疗效及对癌胚抗原、肝肾功能、血压的影响[J]. 中华养生保健, 2022, 40(24): 70-73.

WANG Xiao-li, CAO Yong-feng, ZHOU Yan. Efficacy of Antiangiogenic Targeted Therapy Combined with Chemotherapy in the Treatment of Advanced Lung Cancer and Its Effect on Carcinoembryonic Antigen,Liver and Kidney Function, Blood Pressure[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(24): 70-73.

参考文献

[1] 李婧,张娜.同步放化疗与序贯放化疗治疗晚期肺癌的临床疗效观察[J].中国肿瘤临床与康复,2020,27(1):38-40.
[2] Maiello E, Di Maggio G, Cordio S, et al.Bevacizumab in combination with either FOLFOX-4 or XELOX-2 in first-line treatment of patients with metastatic colorectal cancer: A multicenter randomized phase Ⅱ trial of the gruppo oncologico dell'Italia meridionale (GOIM 2802)[J].Clin Colorectal Cancer,2020,19(2):109-115.
[3] Piawah S, Venook A P.Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer,2019,125(23):4139-4147.
[4] 石远凯. 美国国家癌症综合网非小细胞肺癌治疗指南2008年第二版介绍[J].中华肿瘤杂志,2008,30(5):397-400.
[5] Winter K S, Hofmann F O, Thierfelder K M, et al.基于实体瘤疗效评价标准1.1版(RECIST1.1)中的体积阈值:肝转移瘤治疗效果评估[J].国际医学放射学杂志,2019,42(1):121.
[6] 王永,解华,李凌云.贝伐珠单抗联合厄洛替尼对晚期非小细胞肺癌患者疗效、血清CYFRA21-1水平及KPS评分的影响[J].临床和实验医学杂志,2021,20(8):827-830.
[7] 张琪琳,丁玉峰,戴冰,等.培美曲塞联合贝伐珠单抗维持治疗晚期非鳞状非小细胞肺癌成本-效果分析[J].中国药业,2022,31(10):106-111.
[8] 辛鑫,梁志伟,余会敏,等.支气管动脉化疗栓塞术联合贝伐珠单抗治疗中晚期非小细胞肺癌患者的疗效及其对血浆miR-200a和miR-375表达水平的影响研究[J].实用心脑肺血管病杂志,2022,30(4):37-41.
[9] 李冬,岳成山,胡勇,等.VEGFR2-V297Ⅰ位点基因多态性与贝伐珠单抗联合全脑放疗对非小细胞肺癌脑转移患者的疗效及相关性研究[J].徐州医科大学学报,2022,42(4):248-254.
[10] 陈海韬,杨森森,邓为上,等.贝伐珠单抗生物类似药和原研药治疗非小细胞肺癌有效性、安全性和免疫原性的Meta分析[J].中国药房,2022,33(8):1003-1008.
[11] 姚远方,高飞,张雪松,等.载药微球加载贝伐珠单抗介入栓塞治疗兔VX2肝癌的抗血管生成效果[J].介入放射学杂志,2021,30(3):254-257.
[12] 张青,沈艳琳,王玲.抗血管生成靶向药物治疗肿瘤引起高血压的机制及研究进展[J].现代消化及介入诊疗,2019,26(5):1222-1222.
[13] 卢央芳,仇建波,张占春,等.培美曲塞联合顺铂对晚期非小细胞肺癌的化疗效果和血清肿瘤标志物的影响[J].中国卫生检验杂志,2019,3(9):92-94.
[14] 宋琳,韩芸,魏丽群,等.贝伐珠单抗联合紫杉醇/卡铂方案对晚期非鳞非小细胞肺癌患者相关细胞生长因子及肿瘤标志物的影响[J].实用药物与临床,2020,23(6):36-39.
[15] 谢琳,怀宝华.抗血管生成药物联合紫杉醇和顺铂在非小细胞肺癌中应用价值分析[J].医学临床研究,2021,38(7):1075-1078.
[16] 杨华,魏丽春,张莹,等.联合贝伐珠单抗新辅助化疗+同步放化疗治疗局部晚期巨块型宫颈癌的初步临床研究[J].中华放射肿瘤学杂志,2021,30(4):372-375.